Drug Development & Gene and Cell Therapy Expert Witness | Massachusetts
Drug Development & Gene and Cell Therapy | E-621884
Expert Qualifications
This highly-qualified expert has 14 years of experience in the field of biopharmaceutical development, having earned her BS in biology from the University of North Carolina and her PhD in genetics from the University of California at San Francisco. Her work focuses on drug development with a particular focus on gene and cell therapies, including those with the following elements: AAV, Adenovirus, CRISPR, Zfn, Endonuclease, CAR-T, mRNA, LNP, Lentivirus, HSPC. She has worked in positions such as principal consultant for Halloran Consulting Group, the founder and CEO of Tremont Therapeutics, the senior director of Shire PLC, and the executive director of CRISPR Therapeutics. She is also involved in research in her field as an author of several scientific articles. This expert currently works as the principal at a drug development consulting company in Massachusetts.
Bio Snapshot
Location: MA
BS, Biology, University of North Carolina
PhD, Genetics, University of California, San Francisco
Former, Scientific Education Manager, NIBR Education Office, Novartis Institutes for BioMedical Research
Former, Program Manager, NIBR Drug Discovery Incubator, Novartis Institutes for BioMedical Research
Former, Program Manager, Business Planning and Program Management, Alnylam Pharmaceuticals
Former, Founder and CEO, Tremont Therapeutics
Former, Principal Consultant, Halloran Consulting Group
Former, Early Development Program Leader, Shire PLC
Former, Senior Director, Shire PLC
Former, Program Leader, Hemoglobinopathy, CRISPR Therapeutics
Former, Executive Director, CRISPR Therapeutics
Current, Principal, a drug development consulting company in MA
